Vebreltinib DR is under clinical development by Apollomics and currently in Phase II for Non-Small Cell Lung Cancer.

The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 ... Scientists Discover That Special ...

These survivors, or “cancer thrivers” as some of us prefer to say, helped show me that metastatic cancer is no longer a death sentence.

For decades, treating lung cancer has been like trying to hit a moving target in the dark. Just when doctors think they've found an effective treatment, the cancer adapts and escapes. Now, a team of ...

AstraZeneca PLC has withdrawn its Dato-DXd NSQ NSCLC application from the European Union. The decision marks a significant shift in the company's approach to non-small cell lung cancer treatment ...

AstraZeneca Plc and Daiichi Sankyo Co. have voluntarily withdrawn an application for a lung cancer treatment in the European ...

China's National Medical Products Administration (NMPA) approved Innovent Biologics Inc.’s NDA for Dovbleron (taletrectinib), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for treating ...

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) withdraw EU marketing application for lung cancer therapy Dato-DXd. Read more ...

INR:8904. kalyan guessing fix Amgen's KRAS inhibitor AMG 510 is approved for clinical trials in non-small cell lung cancer in China Available in September, 49 ...